abstract: Aberrant activation of the Wnt/b-catenin pathway occurs in cancers. This review presents several important cancer-related aspects of Wnt/b-catenin signalling relevant to the epididymis, provides evidence of such epididymal gene expression and suggests a new direction for further research. The data presented here indicate that besides containing many Wnt/b-catenin-pathway components, the normal adult human epididymis expresses much more b-catenin than the colorectal carcinoma cell line HCT116, which possesses elevated b-catenin expression. The low cancer incidence in the epididymis may be due to factors present in the human epididymis that regulate this oncogenic Wnt/b-catenin pathway, including (i) 14 of 17 secreted pathway inhibitors, (ii) the majority of the micro-RNAs known to target this pathway, (iii) plasma membrane-associated E-cadherin and CEACAM1 that anchor b-catenin, preventing its availability for nuclear entry and oncogenic transcriptional activity, (iv) the recently identified membrane-located tumourigenesis inhibitors RNF43 and ZNRF3 that mediate the degradation of the Wnt receptor components Fzds and Lrp5/6 and (v) nuclear KLF4, which competes with TCF for b-catenin, limiting its transcriptional activity and stabilizing telomeres, thereby reducing mutation incidence. The above regulatory factors expressed by the human epididymis, and the absence of androgen receptor translocation known to promote nuclear translocation of b-catenin in tumourigenesis in an animal model, may act synergistically to provide hostility in different cell compartments towards tumour formation. The lack of evidence for b-catenin in epididymal nuclei is noteworthy. Studying this phenomenon may help reveal the mechanisms underlying oncogenic Wnt/b-catenin signalling and shed new light on cancer therapy and prevention.
Introduction
The Wnt signalling pathway was first considered to be involved in cancer when Int-1 was identified as an integration site of the mouse mammary tumour virus (Nusse and Varmus, 1982) . The name Wnt derives from a combination of Int and the best-characterized Wnt gene Wg in Drosophila (Nusse et al., 1991) . To date, 19 mammalian Wnt proteins have emerged as versatile mediators of a variety of conditions that include cardiovascular disease, ageing, cell proliferation, cell-fate decisions, cancer, diabetes, neurodegeneration and inflammation (see reviews, Maiese et al., 2008; Staal et al., 2008) . Interrupting the cellular homeostasis of Wnt signalling pathways, especially the canonical Wnt pathway ( Fig. 1 depicts the Wnt/b-catenin signalling pathway components relevant to the epididymis), has a profound effect on human cancer development. There are extensive data demonstrating in human cancers the nuclear localization of b-catenin, a frequently-used surrogate marker of Wnt pathway activation, in addition to the overexpression of pathway activators and loss of pathway inhibitors (Goss and Kahn, 2011) . To date, hyperactivation of the Wnt pathway, or dysregulation of specific components of this pathway, has been observed in almost 50% of all human cancers (see review, Goss and Kahn, 2011) .
The mammalian epididymis is a long convoluted tubule that serves as a conduit for the transport of spermatozoa from the testis to the vas deferens. It is where spermatozoa mature and are stored after acquiring their functions of progressive motility and fertilizing capacity (see reviews Turner, 2008; Cornwall, 2009) . A low tumour incidence is a characteristic of the human epididymis because epididymal cancers, which are mostly not malignant and belong to the 'adenomatoid' class, account for only 0.03% of male cancers (Yeung et al., 2012) . It is possible that the human epididymis lacks tumourigenic stimuli, or has intrinsic inhibitory mechanisms against neoplasia, because it rarely exhibits primary cancer development, metastasis or invasive growth (Ganem et al., 1998; Rizk et al., 1990; Tilki et al., 2008) . A previous review (Yeung et al., 2012) systematically explored the hallmarks of tumourigenic cells and tissues for their relevance in the epididymis, highlighting not only some putative anti-tumour aspects of the epididymis, but also some intriguing oncogenic features of the normal organ. Whether oncogenic Wnt/b-catenin signalling mechanisms are functional in this cancer resistance remains unexplored, despite preliminary detection of its components in the epididymis by microarray assays (Johnston et al., 2005; Zhang et al., 2006; Jelinsky et al., 2007) . Whereas the role of Wnt9B in the embryonic development of the Wolffian duct into the male reproductive tract (Carroll et al., 2005) , of Wnt4 in maintaining epididymal homeostasis (Deshpande et al., 2009 ) and of b-catenin in both the post-natal Figure 1 Schematic diagram of the Wnt/b-catenin signalling pathway and possible crosstalk involving molecules that are found to be expressed in the human epididymis (present data). Wnt off: in the absence of Wnt ligands, b-catenin is targeted for degradation by forming a multi-protein destruction complex with APC, Axin, CK1 and GSK-3b in a ubiquitination-and proteasome-dependent manner. Wnt on: the Wnt ligand binds to Fzd and Lrp5/6 receptors to form an Fz-Lrp5/6 activation complex at the plasma membrane. Secreted Wnt/b-catenin signalling inhibitors are antagonists, which bind to Wnts or Lrp5/6 to inhibit their action. Krm alone can enhance Wnt/b-catenin signalling activation, but inhibits it when bound to DKK. DKK can suppress the activation of the Wnt/b-catenin signalling by both directly and indirectly binding to Lrp6. Formation of the activation complex leads to disassembly of the destruction complex, recruits DVL, Axin, CK1 and GSK-3b to the activation complex and subsequently stabilizes b-catenin, which accumulates, interacts with FoxM1 and translocates to the nucleus, where it interacts with TCF/LEF and other co-activators to drive the transcription of target genes. b-catenin also can directly bind to the androgen receptor and enhance its transcriptional activity. GSK-3b can phosphorylate AR and suppress its transcriptional activity. AJ: b-catenin can form complexes with E-cadherin at the cell membrane and mediate the formation of the AJ. Disruption of AJ sets b-catenin free, which enhances the nuclear translocation of b-catenin and its activation of target genes. Moreover, the nuclear accumulation of the cleaved and internalized extracellular portion of E-cadherin can activate the AP-1 transcription factor pathway to induce cyclin D1 promoter activity. b-catenin can also bind to KLF4 and promote the expression of TERT and thereby maintain telomere length in stem and cancer cells. Like E-cadherin, another adhesion molecule CEACAM1 can function as a tumour suppressor by anchoring b-catenin to the membrane in an E-cadherin-independent manner. Moreover, CEACAM1 can be cleaved and lead to apoptosis induced by CEA. As targets of Wnt/b-catenin signalling, transmembrane E3 ligases RNF43 and ZNRF3 can promote ubiquitin-dependent degradation of Fzds and Lrp5/6 and hence function as Wnt/b-catenin inhibitors. MiRNAs are involved in regulating Wnt/b-catenin signalling, with target molecules indicated in italics.
development of the epididymis (DeBellefeuille et al., 2003; Wu et al., 2012) and the maintenance of epididymal tight junctions in adults (DeBellefeuille et al., 2003) are well known, it is not known if Wnt/ b-catenin signalling has other roles in the adult epididymis. This review is focused only on how permissive the human adult epididymis could be for the oncogenic pathway. In this work, the use for research of human epididymides from young adult accident victim donors at the Organ Transplant Department of the YuHuangDing Hospital, Yantai received permission from the Ethics Committee of the Hospital.
Wnt/b-catenin signalling components in the adult human epididymis
To determine the status of the Wnt/b-catenin signalling pathway in the human epididymis, the protein expression of b-catenin in normal human tissues was examined because enhanced activation of b-catenin in cells of the intestinal villus can lead to increased cell proliferation and the formation of adenomatous lesions (Harada et al., 1999) , the major human epididymal tumour (Yeung et al., 2012) . Unexpectedly, the present study revealed that b-catenin was highly expressed, with the highest signal in the caput epididymidis (Fig. 2) . b-catenin expression in different segments of the human epididymis was also compared with that of a 'fertile human' caput epididymidal cell line 1 (FHCE1) that has characteristics of differentiated principal cells of the adult human epididymis in vivo (Dube et al., 2010a) and with that of other normal and cancer cell lines. As shown in Fig. 3 , b-catenin expression was highest in the caput epididymidis and much higher than that in the metastatic colorectal carcinoma cell line HCT116. This cell line was established from an invasive, metastatic colonic adenocarcinoma and possesses a heterozygous activating mutation in b-catenin (Brattain et al., 1981) , which prevents GSK-3b-mediated phosphorylation (and subsequent proteasomal degradation of b-catenin), so that b-catenin expression is up-regulated (Sekine et al., 2002) . This raises the question 'why does the human epididymis hardly develop cancer with such a high expression of b-catenin?'
Exploration of the Wnt/b-catenin pathway gene components upstream of the nucleus (Fig. 1 ) in both the human epididymis and FHCE1 cells and comparison with databases (http://mrg.genetics. washington.edu/index.cgi; http://humanet.scbit.org/spatial.jsp) (Fig. 4 and Table I) indicated that they were all present, with the exception of SOSTDC1 and KLOTHO, which were present only in the organ. These data suggest that FHCE1 cells could be good models for investigating the role of this pathway in the epididymis and testing epididymal carcinogenesis in vitro. Figure 2 Protein expression of b-catenin (CTNNB1) in human tissues (triplicate estimates of one tissue sample; data are mean + SEM from three gels). Example of protein expression (A) and the quantification (B) of b-catenin in various human tissues by western blotting and densitometry as described by Wang et al., 2012 . Tissues were from organ donors , and antibody against b-catenin (no. 9587) was from Cell Signaling Technology (Danvers, MA, USA). Caput, corpus and cauda represent morphologically and functionally distinct segments from the proximal (caput) to terminal (cauda) regions of the human epididymis (see Fig. 1 in Yeung et al., 2012 for illustration) . Protein levels were normalized to GAPDH abundance (antibody no. 2118, same supplier). Figure 3 Protein expression of b-catenin in human tissues and cell lines (triplicate estimates of one tissue sample; data are mean + SEM from three gels). Example of protein expression (A) and the quantification (B) of b-catenin in different segments of the human epididymis and testis (samples from one man, see Table I ), FHCE1, (generated by Dube et al., 2010a) , non-cancerous and cancerous human cell lines by western blotting and densitometry as described by Wang et al., 2012 . Protein levels were normalized to GAPDH abundance. PC-3, human prostatic carcinoma cells; L-02, normal human hepatocytes; BEL-7402, human hepatocellular carcinoma cells; HCT-116 and HT-29, human colorectal carcinoma cells; HEK293, human embryonic kidney 293; Hela, human cervical carcinoma cells; MCF-7, human breast carcinoma cells.
Epididymal cancer research potential
The Wnt pathway components present in the organ include (i) five canonical pathway-initiating Wnts (Wnt2, Wnt2B, Wnt3, Wnt3A and Wnt9B) that could preferentially initiate Wnt signalling in the human epididymis, (ii) the Wnt receptor genes (FZD3, 4, 6 and 7) and the two Wnt co-receptors (LRP5/6), consistent with the online microarray epididymal data of human, mouse and rat and indicating a conserved role for them in these species, (iii) all major components essential for regulating signal transduction (DVL, Axin, APC, GSK-3a/b and FoxM1) that regulates cytoplasmic b-catenin proteasomal degradation and nuclear entry and (iv) 14 of the 17 currently known secreted inhibitors (see Fig. 1 and Table I ) and two membranelocalized inhibitors (RNF43, ZNRF3), allowing the activation of the intact Wnt/b-catenin signalling pathway to be curtailed. These individual gene expression results are largely consistent with the microarray data in human, mouse and rat epididymides. Microarray data from the human suggest the expression of the nuclear target components, including CBP, TCFs and LEF (http://humanet.scbit.org/spatial.jsp). All this information indicates that the human epididymis should be capable of triggering the oncogenic Wnt/b-catenin signalling pathway, as depicted in Fig. 1 . The significance of the increased expression of some components (Wnt2, APC, APC2, WIF1, FZD1, 2, 5 and 8) by at least 1.4-fold in IHCE1 cells (from infertile men) over those in FHCE1 cells (from fertile men) is not known (Dube et al., 2010b) .
Adhesion molecules interacting with b-catenin in the EMT and in angiogenesis
Considered as the universal adhesion machinery for the generation and maintenance of multi-cellular animal bodies, AJs are detected throughout the metazoan phyla (Oda and Takeichi, 2011) . The E-cadherin/b-catenin complex primarily mediates AJ formation (Ozguven et al., 2011) , and disruption of gene expression, subcellular localization or function of E-cadherin occurs during initiation and progression of almost 90% of all epithelial carcinomas (Pinheiro et al., 2012) . E-cadherin acts as a tumour suppressor by maintaining cellcell adhesion, thereby anchoring b-catenin in the cell membrane (Berx et al., 1995) and making it non-tumourigenic.
Angiogenesis is associated with significant disruption of b-catenin/ E-cadherin complex-mediated AJ of HUVECs (Khaidakov et al., 2012) . The EMT, caused mainly by changes in cadherin -catenin complexes that enable tumour metastasis, demonstrates well the interaction between E-cadherin and b-catenin (Howard et al., 2011) . The EMT can also increase angiogenesis, which is considered essential for tumour progression and metastasis (Derksen et al., 2006; Ceteci et al., 2007; Ma et al., 2010) . The micro-RNAs (miRNAs) miR-32a and miR-9, present in the human epididymis , both suppress E-cadherin expression and trigger EMT in lung and breast cancer cells, respectively (Ma et al., 2010; Cao et al., 2012) . b-catenin released from the disrupted AJs, or by ectopic expression, enhances angiogenesis by up-regulation of VEGF (Kim et al., 2006; Ma et al., 2010) . Interestingly, E-cadherin expression can be down-regulated on binding of the b-catenin/LEF-1 complex to the E-cadherin Table I ) of Wnt/b-catenin signalling components and related important genes (see Fig. 1 ) in the normal human epididymis (epididymis) FHCE1, (generated by Dube et al., 2010a) with GAPDH as an internal control. Primers used for the RT-PCR are given in Supplementary data, 
Inhibitors for Wnt/b-catenin signalling and their receptors 
Other key components (Huber et al., 1996) , and this may trigger a feed-forward loop to enhance the release of b-catenin from the membrane and the activation of its target genes once it enters the nucleus. Like b-catenin, E-cadherin translocates to the nucleus of tumour cells, a localization that is positively correlated with metastatic potential Elston et al., 2009; Cespedes et al., 2010) and that may have diagnostic value for tumours (Ohishi et al., 2012) . E-cadherin may, thus, have a dual function, as does b-catenin, because the N-and C-terminal regions of E-cadherin have been found to be separately responsible for adhesion to the cell membrane and entry into the nucleus (Nose et al., 1990; Salahshor et al., 2008) , and consistent with this, the amount of nuclear E-cadherin has been found to be positively related to the loss of plasma membrane E-cadherin (Elston et al., 2009) . If b-catenin were to participate in the nuclear translocation of E-cadherin in tumour cells, strong and stabilized AJs could suppress tumour progression, or at least reduce the metastatic potential, and this needs to be examined.
A recently identified novel isoform of E-cadherin (CDH1a), which can interact with both b-catenin and p120-catenin, has been shown to increase cell invasion and angiogenesis when co-expressed with canonical E-cadherin, whereas it mimics canonical E-cadherin function when overexpressed in the canonical E-cadherin-negative CHO cell line (Pinheiro et al., 2012) . As a de novo expressed gene in gastric cancer cell lines, it is not known whether CDH1a occurs in epididymal cancers, functions in the manner given above or engages in a crosstalk with Wnt/b-catenin signalling.
AJs are present in the epididymis (Dube et al., 2007) . Both gene and protein expression of E-cadherin are found throughout the epididymis in man (Marín-Briggiler et al., 2008) and rats (Cyr et al., 1992) , where it is localized in the entire cytoplasm of all principal cells (rat) and at the apical and intercellular membranes (human). miRNA-200c has been proved to regulate the expression of E-cadherin in the rat epididymis (Wang and Ruan, 2010a) . Because the regulation of E-cadherin and the regulation of b-catenin are closely related during tumour progression, comparison of the interplay between E-cadherin and b-catenin in cancerous and non-cancerous samples should be a fertile field for research. Another adhesion molecule, CEACAM1, which functions as a tumour suppressor in various epithelial 
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Genes marked p were identified in the present study by RT-PCR with methods as described using primers given in Supplementary data, Table SI . Microarray data were collected from the online database (human: http://humanet.scbit.org/spatial.jsp, mouse and rat: http://mrg.genetics.washington.edu/index.cgi). A, absent; P, present. Genes that cannot be found in the database are marked NF (not found). tumours (Kammerer et al., 2004) , but which also harbours pro-angiogenic properties (Ergun et al., 2000) is expressed unexpectedly at the luminal surface of the epithelium of the normal human epididymis, but is absent from the epithelium of epididymal adenomatoid tumours (Kilic et al., 2010) . This absence is consistent with a role for CEACAM1 in normal epididymal tissue in the prevention of neoplasia via the Wnt/b-catenin pathway because it can directly interact with b-catenin, anchoring it to the cell membrane independently of Ecadherin (Jin et al., 2008) , and it can also mediate the apoptotic pathway in cancer cells (Nittka et al., 2008) . Unlike the situation in most tumours, there is no increased vascular density in adenomatoid epididymal tumour tissue, consistent with lower CEACAM1 staining in intra-tumoral blood vessels and lymphatics around the adenomatoid tissue than that in normal epididymal tissue (Kilic et al., 2010) .
Wnt/b-catenin signalling inhibitors
Secreted mammalian antagonists of the Wnt signalling pathway can be divided into two broad classes according to their mechanisms of action: members of the first group, including the sFRP family WIF-1 and CER1, primarily bind to Wnt proteins, preventing them from binding to their receptors; the second group comprises certain members of the DKK family, which bind to one subunit of the Wnt receptor complex (Kawano and Kypta, 2003) .
Several new inhibitors have recently been identified, and SOST, Wise/SOSTDC1, IGFBP-4, Neucrin/Draxin and KLOTHO belong to the second group (Itasaki et al., 2003; Semenov et al., 2005; Liu et al., 2007; Zhu et al., 2008; Miyake et al., 2009 ) and APCDD1 may represent a third group because it can interact with both Wnt and one subunit of the Wnt receptor complex (Shimomura et al., 2010) . Their significance in normal tissue is suggested by the reduced expression of many of these inhibitors, caused mainly by epigenetic modification, in many cancers (see reviews, Goss and Kahn, 2011; Yao et al., 2011) , but these modifications have not been examined in the epididymis. The presence of these inhibitors has been suggested as diagnostic and prognostic biomarkers for different cancers (Chim et al., 2006; Oberwalder et al., 2008; Yoshino et al., 2009; Zenzmaier et al., 2011; Dellinger et al., 2012; Shen et al., 2012; Xu et al., 2012b) .
Contrarily, these nominally inhibitory factors can also act as activators: Wise can activate the Wnt/b-catenin signalling pathway (Itasaki et al., 2003) , sFRP2 can enhance canonical Wnt3a-induced signalling (von Marschall and Fisher, 2010), DKK1 can stimulate prostatic cancer growth and metastasis (Thudi et al., 2011) , DKK3 is involved in the carcinogenesis of squamous cell carcinoma (Fujii et al., 2011) , the loss of the DKK3 locus (11p15.2) is related to lower lymph node metastasis and better prognosis for head and neck squamous cell carcinomas (Katase et al., 2008) , sFRP2 promotes cell proliferation in ameloblastoma (Sathi et al., 2009) , and IGFBP-4 and SFRP3 can activate the Wnt/b-catenin signal pathway in human renal cancer cells (Hirata et al., 2010; Ueno et al., 2011a) .
The mechanism and regulation of these inhibitors' actions is not yet fully understood in cancer-prone organs, so even more needs to be documented about the role of the secreted inhibitors found in the cancer-resistant epididymis (Fig. 1) .
The current RT-PCR results
show that almost all the inhibitors mentioned above are present in the human epididymis (Fig. 4 and Table I ), where they could prevent the epididymis from succumbing to Wnt/b-catenin-signallingmediated neoplasia. Studying the role of these inhibitors in FHCE1 cells will provide more information on their function in the epididymis.
Other physiological Wnt/b-catenin signalling inhibitors, which are not secreted, include the transmembrane E3 ligases RNF43 and ZNRF3, recently proved to promote turnover of Fzds and Lrp5/6, and to inhibit Wnt/b-catenin signalling (Hao et al., 2012; Koo et al., 2012) . Double knockout of these genes in mice induces Wnt/ b-catenin signalling activation and rapidly-growing adenomas in the intestinal epithelium, which normally expresses RNF43 and ZNRF3. The present data show the expression of both genes in the human epididymis and FHCE1 cells (Fig. 4 and Table I ). Wnt pathway inhibitors in the cytoplasm include the DVL inhibitors NKD, PAR1 and WID, the GSK-3b activator Ajuba, and the b-catenin inhibitors ICAT, Chibby, SERPINA3K, duplin and NLK, many of which have been found to be aberrantly expressed in human cancers and to inhibit Wnt/ b-catenin signalling (see review, Filipovich et al., 2011) . Preliminary microarray data show the presence of Ajuba, Chibby and duplin in the human epididymis (http://humanet.scbit.org/spatial.jsp). It is interesting that the inhibitors RNF43 and ZNRF3 are themselves target genes of the Wnt/b-catenin pathway and thus provide a negative feedback regulation (Hao et al., 2012) . Such a feedback (see Fig. 1 ), serving as a further check on the oncogenic pathway, may be especially relevant for the adult epididymis, where the risk of translocation of b-catenin into the nucleus is high, owing to its normally high expression of beta-catenin.
Regulation of Wnt/b-catenin signalling by miRNAs
Alterations in miRNA levels, their timing of expression or their target recognition can have serious consequences, including cancer (Van Wynsberghe et al., 2011) , because they are involved in almost all aspects of cancer biology: apoptosis, invasion, metastasis and angiogenesis (see review, Cortes-Sempere and Ibanez de Caceres, 2011). miRNAs have been shown to be able to correct the abnormal activation of Wnt/b-catenin signalling with the resultant inhibition of tumour growth, cell viability and motility, and promotion of cell apoptosis in different human cancers (Kim et al., 2011a; Ueno et al., 2011b; Sun et al., 2012) . b-catenin released from disrupted AJs by miRNA-9-mediated E-cadherin reduction, or by ectopic expression, enhances angiogenesis by up-regulation of VEGF in a mouse hind limb ischaemia model and human breast cancer cells (Kim et al., 2006; Ma et al., 2010) . miRNAs have actions in the epididymis unrelated to cancer: miR-200c regulates the expression of E-cadherin in the developing rat epididymis (Wang and Ruan, 2010a) , miR-200a and miR-335 regulate rat epididymal development by directly targeting b-catenin mRNA and RASA1 (Wang and Ruan, 2010b) , respectively, and miR-29a inhibits rat epididymal epithelial proliferation (Ma et al., 2012) . In the human epididymis, miRNAs are expressed in a segmentspecific manner, where they may function directly or indirectly to affect sperm maturation and fertility (Belleannee et al., 2012) .
As many of the miRNAs targeting Wnt/b-catenin signalling are present in the human epididymis (Table II) , the pathway could be finely regulated by them. miR-21 and miR-148a are in the top 10 abundantly expressed miRNA families in the human epididymis and may contribute to the various degrees of resistance to cancer occurring in different segments of the human epididymis (Yeung et al., 2012) .
Hypothetical epididymal cancer stem cells and epithelial spheres
It has been postulated that cancer stem cells (CSCs) are essential for cancer progression because they are immortal, resilient to electromagnetic and chemical insults, able to be quiescent for prolonged periods and can renew themselves and colonize other parts of the body (Clevers, 2011) . In the past few years, sphere-forming assays have been widely used to identify stem cells from their capacity to initiate self-renewal and differentiation of single cells in vitro (Pastrana et al., 2011) . CSCs have been identified in spheres derived from cancerous tissues and cancer cell lines from their CSC-specific surface markers, including CD29, CD44, CD133, OCT4, LGR5/GPR49 and EPCAM/ESA (Shackleton et al., 2006; Kanwar et al., 2010; Cao et al., 2011) . The expression of OCT4 was found to be highest in the human epididymis in a study of splice variants in 52 tissues and cell lines (Johnson et al., 2003) . Moreover, primary human epididymal cell cultures can form spheres expressing OCT4, CD29, CD44 and CD133 (Kristensen et al., 2010) , and all except CD29 are expressed by the normal adult epididymis, but in most if not all epithelial cells, instead of a small subset expected of stem cells (Yeung et al., 2012) . The existence and nature of epididymal CSCs remain inconclusive.
Many of the CSC surface markers, including LGR5/GPR49, CD44, CD24 and EPCAM, some of which are widely expressed by normal epididymal cells (Yeung et al., 2012) , are direct Wnt-signalling targets 
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Inhibit HCC tissues and cell lines Xia et al. (2012) MiRNAs that directly target the Wnt/b-catenin signalling pathway were listed and sorted by their target, function and species. ND, not determined; HCC, human hepatocellular carcinoma. a Present in the human epididymis (Belleannee et al., 2012; Li et al., 2012) . (Goss and Kahn, 2011) . b-catenin is critical for the maintenance of EMT-associated, cancer stem cell-like characters because its activation is correlated with the expression of the CSC marker CD44 . Furthermore, WNT and other genes were identified as neuroblastoma sphere markers in a study in which WNT5A, FZD2, FZD6, DKK2, TCF7L1 and TCF7L2 were up-regulated and cyclin D1 was down-regulated (Coulon et al., 2011) . FZD6 marks rare, highly tumourigenic stem cell-like cells in mouse and human neuroblastomas (Cantilena et al., 2011) . Self-renewal of cancer stem cell-like cells has been reported to be regulated by the Wnt/ b-catenin pathway in human gastric cancer (Cai and Zhu, 2012) . The higher b-catenin expression and activity in colonosphere cells, 80% of which express the CSC marker CD44, than in their parental HCT116 cells, confirms a critical role of the Wnt/b-catenin pathway in regulating growth and maintenance of colonospheres (Kanwar et al., 2010) . Thus, accumulating evidence suggests a role for Wnt/b-catenin signalling in CSCs, and whether this relationship occurs in the human epididymis warrants examination. A novel regulatory role in CSC has been identified for another stem cell marker KLF4. This factor directly binds to the transactivation domain of b-catenin, which inhibits transcriptional co-activator p300/ CBP recruitment and prevents subsequent b-catenin-dependent gene activation (Evans et al., 2010) , thereby antagonizing b-catenin/TCF binding in the nucleus of cancer cells in a concentration-dependent manner (Sellak et al., 2012) . As an inhibitor of colon cancer, KLF4 directly inhibits the expression of Bmi1, which is a potential marker of intestinal stem cells and is required for colon cancer cell proliferation in vivo and in vitro, by crosstalk with the Wnt/b-catenin pathway . Furthermore, in stem cells and human cancer cells, binding of the b-catenin/KLF4 complex to the promoter of TERT up-regulates TERT expression and thereby stabilizes telomere length (Hoffmeyer et al., 2012) , which could be a protective factor against cancers by stabilizing chromosomes against mutations (see review, Eisenberg, 2011) . As KLF4 is highly expressed in the whole epithelium of the mouse epididymis (Godmann et al., 2010) , in the human epididymis and in FHCE1 cells (Fig. 3 and Table I ), it is possible that it couples with the highly expressed epididymal b-catenin to inhibit the oncogenic activity of Wnt/b-catenin signalling and simultaneously to stabilize telomeres.
miR-34 directly targets not only the Wnt/b-catenin pathway but also the CSC markers CD44, CD133 and c-MYC, and inhibits CSCs and cancer metastasis (Siemens et al., 2011) . miR-34 is abundantly expressed in the human epididymis , where it may limit the activation of any CSCs in that organ.
Crosstalk of Wnt/b-cateninwith androgen-signalling at the level of the androgen receptor Androgens are critical for inducing normal differentiation of male reproductive organs, as well as for the development and progression of androgen-dependent prostatic cancers (Kokontis and Liao, 1999) . As 48% of prostatic cancers exhibit dysregulation of Wnt signalling that includes changes in the expression of many activators and inhibitors (Goss and Kahn, 2011) , prostatic cancer has been used as a model to investigate crosstalk between the Wnt/b-catenin and androgen signalling. Four major crosstalk nodes between these two pathways in the prostate cancer cell have been summarized, namely: (i) direct interaction of b-catenin with the AR and promotion of its transcriptional activity in a ligand-dependent fashion, (ii) phosphorylation of AR and suppression of its transcriptional activity by GSK-3b, which mediates phosphorylation and subsequent degradation of b-catenin, (iii) a direct response of the human AR gene as a target of Wnt/b-catenin signalling and (iv) down-regulation of AR expression through an AKT-and MDM2-mediated degradation, which is also apparently activated by Wnt signalling (Terry et al., 2006) . Overexpression of the AR in human prostatic cancer cells can promote Wnt signalling at low androgen levels, and the additional activation of Wnt signalling promotes tumour growth (Schweizer et al., 2008) . A direct interaction between AR and b-catenin would balance Wnt/b-catenin and androgen signalling, orchestrating Wnt3a-induced androgen-independent self-renewal of cells with stem cell characteristics and androgen-dependent proliferation of transit-amplifying cells for prostatic tumour propagation (Bisson and Prowse, 2009 ). Such a mechanism may represent a fifth node.
The epididymis differentiates from the Wolffian duct under the influence of androgens (Murashima et al., 2011) , which are also essential for maintaining epididymal structure and function (Robaire and Hamzeh, 2011) . High AR immunoreactivity has been found in the human prostate and epididymis, where the principal epithelial cells have exclusively nuclear staining (Ruizeveld de Winter et al., 1991) . Both mRNA and protein of the AR are present throughout the epididymis of humans, with more expression proximally than distally (Ungefroren et al., 1997) , as is the case for b-catenin (Figs 2 and 3) . Whether there is any crosstalk between AR and Wnt/b-catenin signalling in the human epididymis as discussed above for prostate cancer is unknown. The role of AR in the nuclear translocation of b-catenin is discussed below.
Nuclear translocation of b-catenin
The fact that human epididymal tumours are several hundred times less common than those in the prostate (Yeung et al., 2012 ) may reflect differences in androgen receptor and b-catenin translocation across the nuclear membranes in the two organs. In rats, such differences between the prostate and epididymis have been reported: the epididymal nuclear AR is resistant to displacement to the cytoplasm after short-term castration or treatment with GnRH-antagonists, whereas a cytoplasmic AR location results in the prostate (Paris et al., 1994) . Furthermore, epididymal b-catenin is released from the lateral plasma membrane by castration, where it accumulates in the cytoplasm (not the nucleus) and returns to the membrane following androgen supplementation (DeBellefeuille et al., 2003) ; in the prostate, however, some membranous b-catenin enters the cytoplasm after castration and some moves to the nucleus after androgen replacement, in parallel with regrowth of the organ (Chesire et al., 2002) .
The contrast between these organs in the androgen-dependent shuttling of the AR out of and b-catenin into the prostatic cell nucleus, and in the apparent exclusion of b-catenin from and retention of the AR within the epididymal cell nucleus, is intriguing, given the difference in cancer susceptibility of the two organs. In human prostatic cancer tissue, the AR is co-localized with b-catenin in the nucleus (Schweizer et al., 2008) , although nuclear b-catenin is independent of androgen level (Whitaker et al., 2008) , and both the human AR (Mulholland et al., 2002) and FoxM1 facilitate b-catenin entry into the nucleus. Whether this mechanism operates in the human epididymis, and if it represents a fundamental difference between these cancer-prone and cancer-resistant organs, remains to be examined.
Perspective
It was suggested in a previous review that the low tumour incidence in the epididymis could be attributable to: (i) prevention of tumour initiation, (ii) detection and destruction of early tumours, (iii) averting proliferation and angiogenesis and (iv) promoting tumour dormancy (Yeung et al., 2012) . Because Wnt/b-catenin signalling is closely related to solid tumours, the existence of this conventional oncogenic pathway in the human epididymis and its potential role in epididymal tumorigenesis were explored here. In apparent contrast to the current consensus was the high amount of b-catenin that the normal organ harboured, in the absence of neoplasia. Moreover, the exhibition of 30 and 60% of epididymal cancers in the caput and cauda epididymidis, respectively (Yeung et al., 2012) , is the opposite of the decreasing trend of b-catenin expression between these regions. This paradox of high b-catenin expression associated with low tumour incidence suggests the existence of an inhibition in the epididymis of the conventional tumourigenic pathway. Indeed, there was major expression in the human epididymis of (i) the genes of many inhibitors of the Wnt/b-catenin pathway, (ii) miRNAs targeting the Wnt/b-catenin pathway, (iii) the b-catenin-binding proteins E-cadherin and CEACAM, which together may enable this organ to evade tumourigenesis and explain the low epithelial proliferation rate and rare malignancy (Yeung et al., 2012) .
Because the oncogenic Wnt/b-catenin pathway has the potential to regulate cancer-related hallmarks, such as cell proliferation, metastasis, angiogenesis, telomerase activity, apoptosis and CSCs, mechanisms underlying these in the cancer-resistant epididymis need to be investigated (see Fig. 1 ). Because tumourigenesis involves complex mechanisms, these challenging aspects of cell physiology and interaction should be addressed in the future. Introducing cancer-resistant organ models, such as the epididymis and epididymal cell lines, for further research should provide opportunities to understand better the nuances of the Wnt/b-catenin signalling pathway and help to find new treatments for cancers related to this pathway.
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